Comparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method

NCT ID: NCT01399333

Last Updated: 2011-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to compare the varying qualities of protein supplements utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) method and evaluating the clinical outcome related to protein stores and absorption.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PDCAAS has been adopted by the Food and Agricultural Organization (FAO) of the World Health Organization (WHO) and is currently recognized as the standard method to evaluate protein quality. This study will also examine patient tolerability, satiety, and satisfaction while using meal replacements versus protein supplements. This research study looks to gain knowledge on the varying qualities of protein and find the most effective protein supplement and/or meal replacement that provides increased patient compliance and promotes a healthy recovery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Protein Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

full liquid diet utilizing meal replacements with PDCAAS of 1.0

Group Type ACTIVE_COMPARATOR

Group 1 Meal Replacement

Intervention Type DIETARY_SUPPLEMENT

4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Group 2

full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99

Group Type ACTIVE_COMPARATOR

Group 2 Protein Supplement

Intervention Type DIETARY_SUPPLEMENT

4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Group 3

full liquid diet utilizing protein supplement with a PDCAAS less than 0.5

Group Type ACTIVE_COMPARATOR

Group 3

Intervention Type DIETARY_SUPPLEMENT

4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group 1 Meal Replacement

4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Intervention Type DIETARY_SUPPLEMENT

Group 2 Protein Supplement

4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Intervention Type DIETARY_SUPPLEMENT

Group 3

4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persons that are scheduled to undergo the adjustable gastric banding (AGB) surgery utilizing the AP Lap-Band System.

Exclusion Criteria

* Willing to comply with food and exercise logs and comply with the full-liquid diet, both pre-and-post-operatively.


* Persons who are not undergoing AGB surgery or are unwilling to comply with study methods or are medically not eligible.
* Taking diuretics
* Have been diagnosed with unstable diabetes, unstable neurologic conditions, unstable cardiac conditions or gastro-intestinal disorders, renal dysfunction, wounds, and autoimmune disorders that may increase protein needs.
* Uncontrolled gastrointestinal disease, such as Crohn's disease, diverticulitis, Celiac disease, or ulcerative colitis.
* Active malignancy
* Patients will also be excluded if pre-operative vitamin deficiencies are not corrected by surgery.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of North Carolina, Charlotte

OTHER

Sponsor Role collaborator

Southeast Bariatrics, PA

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Southeast Bariatrics, an affiliate of Novant Medical Group

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David C Voellinger, MD

Role: PRINCIPAL_INVESTIGATOR

Southeast Bariatrics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southeast Bariatrics

Charlotte, North Carolina, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mary Sha Miller, RN, CBN

Role: CONTACT

704-347-4144 ext. 216

Mary C Head, ANP

Role: CONTACT

704-347-4144 ext. 220

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mary Sha Miller, RN, CBN

Role: primary

704-347-4144 ext. 216

Mary C Head, ANP

Role: backup

704-347-4144 ext. 220

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Protein Intake & Insulin Action
NCT02004002 COMPLETED NA